Back to Search Start Over

Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy.

Authors :
Chen JH
Nieman LT
Spurrell M
Jorgji V
Elmelech L
Richieri P
Xu KH
Madhu R
Parikh M
Zamora I
Mehta A
Nabel CS
Freeman SS
Pirl JD
Lu C
Meador CB
Barth JL
Sakhi M
Tang AL
Sarkizova S
Price C
Fernandez NF
Emanuel G
He J
Van Raay K
Reeves JW
Yizhak K
Hofree M
Shih A
Sade-Feldman M
Boland GM
Pelka K
Aryee MJ
Mino-Kenudson M
Gainor JF
Korsunsky I
Hacohen N
Source :
Nature immunology [Nat Immunol] 2024 Apr; Vol. 25 (4), pp. 644-658. Date of Electronic Publication: 2024 Mar 19.
Publication Year :
2024

Abstract

The organization of immune cells in human tumors is not well understood. Immunogenic tumors harbor spatially localized multicellular 'immunity hubs' defined by expression of the T cell-attracting chemokines CXCL10/CXCL11 and abundant T cells. Here, we examined immunity hubs in human pre-immunotherapy lung cancer specimens and found an association with beneficial response to PD-1 blockade. Critically, we discovered the stem-immunity hub, a subtype of immunity hub strongly associated with favorable PD-1-blockade outcome. This hub is distinct from mature tertiary lymphoid structures and is enriched for stem-like TCF7 <superscript>+</superscript> PD-1 <superscript>+</superscript> CD8 <superscript>+</superscript> T cells, activated CCR7 <superscript>+</superscript> LAMP3 <superscript>+</superscript> dendritic cells and CCL19 <superscript>+</superscript> fibroblasts as well as chemokines that organize these cells. Within the stem-immunity hub, we find preferential interactions between CXCL10 <superscript>+</superscript> macrophages and TCF7 <superscript>-</superscript> CD8 <superscript>+</superscript> T cells as well as between mature regulatory dendritic cells and TCF7 <superscript>+</superscript> CD4 <superscript>+</superscript> and regulatory T cells. These results provide a picture of the spatial organization of the human intratumoral immune response and its relevance to patient immunotherapy outcomes.<br /> (© 2024. The Author(s), under exclusive licence to Springer Nature America, Inc.)

Details

Language :
English
ISSN :
1529-2916
Volume :
25
Issue :
4
Database :
MEDLINE
Journal :
Nature immunology
Publication Type :
Academic Journal
Accession number :
38503922
Full Text :
https://doi.org/10.1038/s41590-024-01792-2